Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses

Lyubomir A Dourmishev, Dimitrina V Guleva, Ljubka G Miteva, Lyubomir A Dourmishev, Dimitrina V Guleva, Ljubka G Miteva

Abstract

Intravenous immunoglobulins (IVIGs), a mixture of variable amounts of proteins (albumin, IgG, IgM, IgA, and IgE antibodies), as well as salt, sugar, solvents, and detergents, are successfully used to treat a variety of dermatological disorders. For decades, IVIGs have been administered for treatment of infectious diseases and immune deficiencies, since they contain natural antibodies that represent a first-line defense against pathogens. Today their indication has expanded, including the off-label therapy for a variety of autoimmune and inflammatory diseases. In dermatology, IVIGs are administered for treatment of different disorders at different therapeutic regimens, mostly with higher doses then those administered for treatment of infectious diseases. The aim of this prospective review is to highlight the indications, effectiveness, side effects, and perspectives of the systemic treatment with IVIGs for patients with severe, life-threatening, and resistant to conventional therapies autoimmune or inflammatory dermatoses.

References

    1. Kazatchkine M. D., Kaveri S. V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. The New England Journal of Medicine. 2001;345(10):747–755. doi: 10.1056/nejmra993360.
    1. Andersson J., Skansen-Saphir U., Sparrelid E., Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clinical & Experimental Immunology. 1996;104:10–21.
    1. Hurez V., Kaveri S. V., Mouhoub A., et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg) Therapeutic Immunology. 1994;1(5):269–277.
    1. Marchalonis J. J., Kaymaz H., Dedeoglu F., Schluter S. F., Yocum D. E., Edmundson A. B. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(8):3325–3329. doi: 10.1073/pnas.89.8.3325.
    1. Tha-In T., Bayry J., Metselaar H. J., Kaveri S. V., Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends in Immunology. 2008;29(12):608–615. doi: 10.1016/j.it.2008.08.004.
    1. Toyoda M., Pao A., Petrosian A., Jordan S. C. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. American Journal of Transplantation. 2003;3(2):156–166. doi: 10.1034/j.1600-6143.2003.00011.x.
    1. Kazatchkine M. D., Dietrich G., Hurez V., et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig) Immunological Reviews. 1994;139(1):79–107. doi: 10.1111/j.1600-065x.1994.tb00858.x.
    1. Dwyer J. M. Manipulating the immune system with immuneglobulin. The New England Journal of Medicine. 1992;326:107–116. doi: 10.1056/nejm199201093260206.
    1. Samuelsson A., Towers T. L., Ravetch J. V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291(5503):484–486. doi: 10.1126/science.291.5503.484.
    1. Ruiz de Souza V., Carreno M.-P., Kaveri S. V., et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin) European Journal of Immunology. 1995;25(5):1267–1273. doi: 10.1002/eji.1830250521.
    1. Bayry J., Lacroix-Desmazes S., Carbonneil C., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101(2):758–765. doi: 10.1182/blood-2002-05-1447.
    1. Bayry J., Lacroix-Desmazes S., Delignat S., et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-α present in serum from patients with systemic lupus erythematosus. Arthritis & Rheumatism. 2003;48(12):3497–3502. doi: 10.1002/art.11346.
    1. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490–493. doi: 10.1126/science.282.5388.490.
    1. Prasad N. K. A., Papoff G., Zeuner A., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. Journal of Immunology. 1998;161(7):3781–3790.
    1. Basta M., Fries L. F., Frank M. M. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood. 1991;77(2):376–380.
    1. Lutz H. U., Stammler P., Bianchi V., et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood. 2004;103(2):465–472. doi: 10.1182/blood-2003-05-1530.
    1. Paquet P., Kaveri S., Jacob E., Pirson J., Quatresooz P., Piérard G. E. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Experimental Dermatology. 2006;15(5):381–386. doi: 10.1111/j.0906-6705.2006.00426.x.
    1. Schwartz R. A., McDonough P. H., Lee B. W. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. Journal of the American Academy of Dermatology. 2013;69(2):173.e1–173.e13. doi: 10.1016/j.jaad.2013.05.003.
    1. Trent J. T., Kirsner R. S., Romanelli P., Kerdel F. A. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the university of Miami experience. Archives of Dermatology. 2003;139(1):39–43. doi: 10.1001/archderm.139.1.39.
    1. Tan A. W., Thong B. Y., Yip L. W., Chng H. H., Ng S. K. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. Journal of Dermatology. 2005;32(1):1–6. doi: 10.1111/j.1346-8138.2005.tb00704.x.
    1. Tan S.-K., Tay Y.-K. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Dermato-Venereologica. 2012;92(1):62–66. doi: 10.2340/00015555-1169.
    1. Trent J., Halem M., French L. E., Kerdel F. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Seminars in Cutaneous Medicine and Surgery. 2006;25(2):91–93. doi: 10.1016/j.sder.2006.04.004.
    1. Aihara M., Kano Y., Fujita H., et al. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. The Journal of Dermatology. 2015;42(8):768–777. doi: 10.1111/1346-8138.12925.
    1. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nature Medicine. 2004;10(1):17–18. doi: 10.1038/nm0104-17.
    1. Bystryn J.-C., Jiao D., Natow S. Treatment of pemphigus with intravenous immunoglobulin. Journal of the American Academy of Dermatology. 2002;47(3):358–363. doi: 10.1067/mjd.2002.122735.
    1. Baum S., Scope A., Barzilai A., Azizi E., Trau H. The role of IVIg treatment in severe pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology. 2006;20(5):548–552.
    1. Ahmed A. R., Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. Journal of the American Academy of Dermatology. 2002;46(1):42–49. doi: 10.1067/mjd.2002.116338.
    1. Beckers R. C. Y., Brand A., Vermeer B. J., Boom B. W. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. British Journal of Dermatology. 1995;133(2):289–293. doi: 10.1111/j.1365-2133.1995.tb02631.x.
    1. Ahmed A. R. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. Journal of the American Academy of Dermatology. 2001;45(6):825–835. doi: 10.1067/mjd.2001.116337.
    1. Nguyen T., Alraqum E., Razzaque Ahmed A. Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis. International Immunopharmacology. 2015;26(1):1–3. doi: 10.1016/j.intimp.2015.02.038.
    1. Urcelay M. L., McQueen A., Douglas W. S. Cicatricial pemphigoid treated with intravenous immunoglobulin. British Journal of Dermatology. 1997;137(3):477–478.
    1. Sami N., Bhol K. C., Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clinical Immunology. 2002;102(1):59–67. doi: 10.1006/clim.2001.5150.
    1. Meier F., Sonnichsen K., Schaumburg-Lever G., Dopfer R., Rassner G. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. Journal of the American Academy of Dermatology. 1993;29(2):334–337. doi: 10.1016/0190-9622(93)70189-z.
    1. Gourgiotou K., Exadaktylou D., Aroni K., et al. Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins. Journal of the European Academy of Dermatology and Venereology. 2002;16(1):77–80. doi: 10.1046/j.1468-3083.2002.00386.x.
    1. Khan I. U., Bhol K. C., Ahmed A. R. Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. Journal of the American Academy of Dermatology. 1999;40(3):485–488. doi: 10.1016/s0190-9622(99)70504-9.
    1. Goebeler M., Seitz C., Rose C., et al. Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins. British Journal of Dermatology. 2003;149:912–914.
    1. Dalakas M. C., Illa I., Dambrosia J. M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. The New England Journal of Medicine. 1993;329(27):1993–2000. doi: 10.1056/nejm199312303292704.
    1. Sadayama T., Miyagawa S., Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. Journal of Dermatology. 1999;26(7):457–459. doi: 10.1111/j.1346-8138.1999.tb02026.x.
    1. Saito E., Koike T., Hashimoto H., et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Modern Rheumatology. 2008;18(1):34–44. doi: 10.1007/s10165-007-0013-0.
    1. Imataka G., Arisaka O. Long-term, high-dose intravenous immunoglobulin therapy in a patient with banker-type juvenile dermatomyositis. Cell Biochemistry and Biophysics. 2014;69(3):747–748. doi: 10.1007/s12013-014-9833-7.
    1. Patil A. K. B., Prabhakar A. T., Sivadasan A., Alexander M., Chacko G. An unusual case of inflammatory necrotizing myopathy and neuropathy with pipestem capillaries. Neurology India. 2015;63(1):72–76. doi: 10.4103/0028-3886.152642.
    1. Danieli M. G., Gambini S., Pettinari L., Logullo F., Veronesi G., Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmunity Reviews. 2014;13(10):1048–1054. doi: 10.1016/j.autrev.2014.08.023.
    1. Lampropoulos C. E., Hughes G. R. V., D'Cruz D. P. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clinical Rheumatology. 2007;26(6):981–983. doi: 10.1007/s10067-006-0222-5.
    1. Ky C., Swasdibutra B., Khademi S., Desai S., Laquer V., Grando S. A. Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept study. Dermatology Reports. 2015;7(1, article 5804) doi: 10.4081/dr.2015.5804.
    1. Levy Y., Amital H., Langevitz P., et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis & Rheumatism. 2004;50(3):1005–1007. doi: 10.1002/art.20195.
    1. Matsuda M., Miki J., Oguchi K., Tabata K., Ikeda S.-I. Fasciitis in mixed connective tissue disease successfully treated with high-dose intravenous immunoglobulin. Internal Medicine. 2003;42(9):910–911. doi: 10.2169/internalmedicine.42.910.
    1. Wakim M., Alazard M., Yajima A., Speights D., Saxon A., Stiehm E. R. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Annals of Allergy, Asthma and Immunology. 1998;81(2):153–158. doi: 10.1016/S1081-1206(10)62802-5.
    1. Paul C., Lahfa M., Bachelez H., Chevret S., Dubertret L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. British Journal of Dermatology. 2002;147(3):518–522. doi: 10.1046/j.1365-2133.2002.04833.x.
    1. O'Donnell B. F., Barr R. M., Kobza Black A., et al. Intravenous immunoglobulin in autoimmune chronic urticaria. British Journal of Dermatology. 1998;138(1):101–106. doi: 10.1046/j.1365-2133.1998.02033.x.
    1. Parodi E., Giordano P., Rivetti E., et al. Efficacy of combined intravenous immunoglobulins and steroids in children with primary immune thrombocytopenia and persistent bleeding symptoms. Blood Transfusion. 2014;12(3):340–345. doi: 10.2450/2014.0185-13.
    1. Lee J. H., Lee K. S. Efficacy of very low-dose (200 mg/kg/d) with short-term intravenous immunoglobulin G therapy according to individual response of acute immune thrombocytopenic purpura in childhood. Clinical Pediatric Hematology-Oncology. 2006;13(2):143–149.
    1. Peng J., Ma S.-H., Liu J., et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. Journal of Thrombosis and Haemostasis. 2014;12(4):497–504. doi: 10.1111/jth.12524.
    1. Newburger J. W., Takahashi M., Beiser A. S., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. The New England Journal of Medicine. 1991;324(23):1633–1639. doi: 10.1056/nejm199106063242305.
    1. Dourmishev A. L., Serafimova D. K., Vassileva S. G., Dourmishev L. A., Schwartz R. A. Segmental ulcerative vasculitis: a cutaneous manifestation of Takayasu's arteritis. International Wound Journal. 2005;2(4):332–345. doi: 10.1111/j.1742-4801.2005.00103.x.
    1. DeFilippis E. M., Feldman S. R., Huang W. W. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. British Journal of Dermatology. 2014;172(6):1487–1497.
    1. Gupta A. K., Shear N. H., Sauder D. N. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. Journal of the American Academy of Dermatology. 1995;32(1):140–142. doi: 10.1016/0190-9622(95)90218-X.
    1. Dobson C. M., Parslew R. A., Evans S. Superficial granulomatous pyoderma treated with intravenous immunoglobulin. Journal of the American Academy of Dermatology. 2003;48(3):456–460. doi: 10.1067/mjd.2003.172.
    1. Cafardi J., Sami N. Intravenous immunoglobulin as salvage therapy in refractory pyoderma gangrenosum: report of a case and review of the literature. Case Reports in Dermatology. 2014;6(3):239–244. doi: 10.1159/000368824.
    1. Lister R. K., Jolles S., Whittaker S., et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg) Journal of the American Academy of Dermatology. 2000;43(2):403–408. doi: 10.1067/mjd.2000.104001.
    1. Kumar N., Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Multiple Sclerosis. 2004;10(1):85–86. doi: 10.1191/1352458504ms987cr.
    1. Antonelli A., Navarranne A., Palla R., et al. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid. 1994;4(4):399–408. doi: 10.1089/thy.1994.4.399.
    1. Terheyden P., Kahaly G. J., Zillikens D., Bröcker E.-B. Lack of response of elephantiasic pretibial myxoedema to treatment with high-dose intravenous immunoglobulins. Clinical and Experimental Dermatology. 2003;28(2):224–226. doi: 10.1046/j.1365-2230.2003.01232_3.x.
    1. Prins C., Gelfand E. W., French L. E. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Dermato-Venereologica. 2007;87(3):206–218. doi: 10.2340/00015555-0249.
    1. Palabrica F. R., Kwong S. L., Padua F. R. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pacific Allergy. 2013;3(4):249–256. doi: 10.5415/apallergy.2013.3.4.249.
    1. Vecchietti G., Kerl K., Prins C., Kaya G., Saurat J.-H., French L. E. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Archives of Dermatology. 2006;142(2):213–217. doi: 10.1001/archderm.142.2.213.
    1. Kurata M., Horie C., Kano Y., Shiohara T. Pompholyx as a clinical manifestation suggesting increased serum IgG levels in a patient with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. British Journal of Dermatology. 2015 doi: 10.1111/bjd.14200.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren